Welcome to our dedicated page for Kraig Biocraft Laboratories In news (Ticker: KBLB), a resource for investors and traders seeking the latest updates and insights on Kraig Biocraft Laboratories In stock.
Kraig Biocraft Laboratories reports recurring developments in recombinant spider silk technology, including production scale-up, new rearing capacity, cocoon output, and downstream reeling into usable silk fiber. The company’s technology is built around scientifically engineered silkworms that incorporate key spider silk proteins, with updates often tied to commercialization of materials for technical textiles, luxury wear, performance apparel, and other high-performance applications.
KBLB news also covers R&D execution, strain development, yield optimization, fiber performance, South East Asia production activity, and coordination with Prodigy Silk and related production networks.
Kraig Biocraft Laboratories (OTCQB: KBLB) has taken possession of its third silkworm rearing center, completing core infrastructure upgrades for a 2026 production scale-up.
With three operational rearing centers the company says it can run three simultaneous production cycles and aims to exceed one metric ton of finished spider silk per month, supported by newly acquired mulberry fields for feedstock. Operations are expected to begin later this quarter.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced it has taken possession of three mulberry fields and integrated that feedstock into active silkworm rearing to advance a planned production ramp-up. Mulberry leaf from these fields will support deployment of more than 1,000,000 BAM-1 Alpha production hybrid eggs now scheduled for release. The fields' proximity to company facilities is cited as providing logistical efficiencies, feedstock consistency, and supply security. Kraig Labs also noted access to additional mulberry fields through a collaboration with a Southeast Asia government office, which the company says can remove fixed capacity constraints and support rapid growth toward sustained commercial output.
Kraig Biocraft Laboratories (OTCQB: KBLB) completed a production cycle delivering more than one million BAM-1 Alpha hybrid eggs on Dec. 15, 2025. The eggs are staged for release over the next quarter to support recombinant spider silk production.
The company says BAM-1 Alpha provides greater uniformity, resiliency, throughput and consistency, enabling an accelerated 6-month production schedule and supporting expansion initiatives in Southeast Asia.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced on Dec 8, 2025 that it has been granted usage rights to a block of government-owned mulberry gardens near its Southeast Asia spider silk production facilities. The company will pay a nominal rent and will incorporate the gardens into its production pipeline to supply mulberry leaf feedstock for scaled-up recombinant spider silk manufacturing, including BAM-1 Alpha hybrid yarns.
This land access is intended to improve supply reliability, logistics, and the company's ability to support a recently announced pilot order from a leading performance sports apparel brand as Kraig Labs advances toward broader commercialization.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced a hiring initiative on November 25, 2025 to expand production staffing at its Southeast Asia operations as throughput and its production footprint increase. The company is recruiting and training new production staff to support a new production center currently in development, with specialized sericulture training led by Dr. Nirmal Kumar.
The expansion aims to increase capacity, resilience, and commercial production of the company's recombinant spider silk over the coming quarters, and Kraig Labs said it expects to continue adding staff and resources as facilities are developed.
Kraig Biocraft Laboratories (OTCQB: KBLB) is fulfilling an order of its next-generation recombinant spider silk yarns for a confidential pilot program with a globally recognized performance sports apparel brand.
The company is converting part of its spider silk inventory into yarns tailored to the customer's specifications; delivery is expected before the end of the first quarter of 2026. The pilot uses a small, purpose-built quantity intended to demonstrate commercial and performance potential while details remain confidential.
Kraig Biocraft Laboratories (OTCQB: KBLB) confirmed on Nov 3, 2025 that its spider silk production operations in Vietnam remained fully secure and uninterrupted after recent Southeast Asia typhoons.
The company cited its 2024 relocation to protected highlands, complete September relocation from its former Quang Nam facility, and a strategy of multiple parallel production sites as the reasons operations and mulberry feedstock suffered no damage or disruption.
Kraig Biocraft Laboratories (OTCQB: KBLB) promoted Dr. Xiaoli Zhang to Chief Scientist on October 27, 2025 after leading a series of scientific breakthroughs in spider silk-based super materials. Dr. Zhang joined Kraig Labs in October 2024 and, according to the company, accelerated the research program to exceed milestones and advance next-generation fiber and bioengineered materials.
The announcement highlights breakthroughs in spider silk production at the company's operations centers in Southeast Asia and frames the promotion as part of Kraig Labs' push to commercialize sustainable, higher-margin performance materials.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced the start of its sixth 2025 spider silk production cycle on October 20, 2025, introducing the first large-scale deployment of its BAM-1 Alpha recombinant spider silk hybrid.
The company says BAM-1 Alpha builds on 2024 breakthroughs to deliver stronger performance and higher silk yields while fitting existing production schedules and infrastructure. The cycle scales parental lines and continues use of diapause egg management to improve efficiency, logistics, and sustained throughput across cycles.
Kraig Biocraft Laboratories (OTCQB: KBLB) announced a selective breeding advancement that materially increases recombinant spider silk production throughput. By mating an improved parental strain with a BAM-1 parent, the Company created the BAM-1 Alpha hybrid, which demonstrated 22% higher cocoon shell weight (the company's measure of silk output) and an increase in hybrid vigor of more than 245% versus the original BAM-1. BAM-1 Alpha will be deployed across Kraig's multi-facility production infrastructure to support commercial manufacturing and lower per-unit production cost, while robustness data beyond shell weight remains unquantified.